{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:14:17Z","timestamp":1790712857929,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Kanagawa Prefectural Cancer foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fluorouracil, leucovorin (5FU\/LV), and nanoliposomal-irinotecan (nal-IRI) combination therapy has been established as the second-line treatment for advanced pancreatic ductal adenocarcinoma. Oxaliplatin with 5FU\/LV (FOLFOX) is often used as a subsequent treatment, although its efficacy and safety are yet to be fully elucidated. We aimed to evaluate the efficacy and safety of FOLFOX as a third- or later-line treatment for patients with advanced pancreatic ductal adenocarcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a single-centre, retrospective study that enrolled 43 patients who received FOLFOX after failure of gemcitabine-based regimen followed by 5FU\/LV\u2009+\u2009nal-IRI therapy between October 2020 and January 2022. FOLFOX therapy consisted of oxaliplatin (85\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ), levo-leucovorin calcium (200\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) and 5-FU (2400\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) every 2 weeks per cycle. Overall survival, progression-free survival, objective response, and adverse events were evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At the median follow-up time of 3.9\u2009months in all patients, the median overall survival and progression-free survival were 3.9\u2009months (95% confidence interval [CI], 3.1\u20134.8) and 1.3\u2009months (95% CI, 1.0\u20131.5), respectively. Response and disease control rates were 0 and 25.6%, respectively. The most common adverse event was anaemia in all grades followed by anorexia; the incidence of anorexia and grades 3 and 4 was 21 and 4.7%, respectively. Notably, grades 3\u20134 peripheral sensory neuropathy was not observed. Multivariable analysis revealed that a C-reactive protein (CRP) level of &gt;\u20091.0\u2009mg\/dL was a poor prognostic factor for both progression-free survival and overall survival: hazard ratios were 2.037 (95% CI, 1.010\u20134.107;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.047) and 2.471 (95% CI, 1.063\u20135.745;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.036), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>FOLFOX as a subsequent treatment after failure of second-line treatment with 5FU\/LV\u2009+\u2009nal-IRI is tolerable, although its efficacy is limited, particularly in patients with high CRP levels.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-023-10654-3","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T18:02:42Z","timestamp":1677002562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study"],"prefix":"10.1186","volume":"23","author":[{"given":"Satoshi","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Tezuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Yamachika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Tsunoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Tozuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taito","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,21]]},"reference":[{"key":"10654_CR1","unstructured":"International Agency for Research on Cancer. GLOBOCAN. https:\/\/gco.iarc.fr\/. Accessed 10 Aug 2022."},{"key":"10654_CR2","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"},{"key":"10654_CR3","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med"},{"key":"10654_CR4","volume-title":"Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma. Version 1","author":"NCCN","year":"2022","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma. Version 1.2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf. Accessed 10 Aug 2022."},{"key":"10654_CR5","unstructured":"Clinical Practice Guidelines for Pancreatic Cancer 2022. (in Japanese); Japan Panrease Society. Published on 8 July, 2022."},{"key":"10654_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387:545\u201357.","journal-title":"Lancet"},{"key":"10654_CR7","doi-asserted-by":"publisher","first-page":"9396","DOI":"10.1002\/cam4.3558","volume":"9","author":"M Ueno","year":"2020","unstructured":"Ueno M, Nakamori S, Sugimori K, Kanai M, Ikeda M, Ozaka M, et al. Nal-IRI+5-FU\/LV versus 5-FU\/LV in post-gemcitabine metastatic pancreatic cancer: randomized phase 2 trial in Japanese patients. Cancer Med. 2020;9:9396\u2013408.","journal-title":"Cancer Med"},{"key":"10654_CR8","doi-asserted-by":"crossref","unstructured":"Tezuka S, Ueno M, Kobayashi S, Hamaguchi T, Yamachika Y, Oishi R, et al. Nal-IRI\/5-FU\/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: a single center retrospective study.\u00a0Pancreatology. 2022;22:789\u201396.","DOI":"10.1016\/j.pan.2022.06.004"},{"key":"10654_CR9","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","volume":"32","author":"H Oettle","year":"2014","unstructured":"Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014;32:2423\u20139.","journal-title":"J Clin Oncol"},{"key":"10654_CR10","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1200\/JCO.2016.68.5776","volume":"34","author":"S Gill","year":"2016","unstructured":"Gill S, Ko YJ, Cripps C, Beaudoin A, Dhesy-Thind S, Zulfiqar M, et al. PANCREOX: a randomized phase III study of fluorouracil\/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol. 2016;34:3914\u201320.","journal-title":"J Clin Oncol"},{"key":"10654_CR11","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/bjc.2015.103","volume":"112","author":"S Ohkawa","year":"2015","unstructured":"Ohkawa S, Okusaka T, Isayama H, Fukutomi A, Yamaguchi K, Ikeda M, et al. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer. 2015;112:1428\u201334.","journal-title":"Br J Cancer"},{"key":"10654_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (version 1.1). 2009;45:228\u201347.","journal-title":"Eur J Cancer (version 1.1)"},{"key":"10654_CR13","unstructured":"National Cancer Institute Cancer Therapy Evaluation Program. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50. Accessed 10 Aug, 2022."},{"key":"10654_CR14","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.3390\/curroncol29040216","volume":"29","author":"T Yamai","year":"2022","unstructured":"Yamai T, Ikezawa K, Kawamoto Y, Hirao T, Higashi S, Daiku K, et al. 5-fluorouracil\/L-leucovorin plus oxaliplatin (FOLFOX) regimen as salvage chemotherapy for patients with unresectable pancreatic cancer receiving gemcitabine and nab-paclitaxel and 5-fluorouracil\/L-leucovorin plus nanoliposomal irinotecan: preliminary results from clinical practice. Curr Oncol. 2022;29:2644\u20139.","journal-title":"Curr Oncol"},{"issue":"4_suppl","key":"10654_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1200\/JCO.2019.37.4_suppl.189","volume":"37","author":"M Unno","year":"2019","unstructured":"Unno M, Motoi F, Matsuyama Y, Satoi S, Matsumoto I, Aosasa S, et al. Randomized phase II\/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02\/JSAP-05). J Clin Oncol. 2019;37(4_suppl):189.","journal-title":"J Clin Oncol"},{"key":"10654_CR16","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","volume":"389","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011\u201324.","journal-title":"Lancet"},{"key":"10654_CR17","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395\u2013406.","journal-title":"N Engl J Med"},{"key":"10654_CR18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248\u201357.","journal-title":"Lancet"},{"key":"10654_CR19","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1245\/s10434-014-4225-1","volume":"22","author":"M Blazer","year":"2015","unstructured":"Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline Resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2015;22:1153\u20139.","journal-title":"Ann Surg Oncol"},{"key":"10654_CR20","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/bjc.2016.45","volume":"114","author":"SM Stein","year":"2016","unstructured":"Stein SM, James ES, Deng Y, Cong X, Kortmansky JS, Li J, et al. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer. 2016;114:737\u201343.","journal-title":"Br J Cancer"},{"key":"10654_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1081\/CNV-46502","volume":"23","author":"N Androulakis","year":"2005","unstructured":"Androulakis N, Syrigos K, Polyzos A, Aravantinos G, Stathopoulos GP, Ziras N, et al. Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study. Cancer Investig. 2005;23:9\u201312.","journal-title":"Cancer Investig"},{"key":"10654_CR22","doi-asserted-by":"crossref","unstructured":"Hank T, Hinz U, Reiner T, Malleo G, K\u00f6nig AK, Maggino L, et al. A pretreatment prognostic score to stratify survival in pancreatic cancer.\u00a0Ann Surg. 2022;276:e914\u2013e22.","DOI":"10.1097\/SLA.0000000000004845"},{"key":"10654_CR23","doi-asserted-by":"publisher","first-page":"8781","DOI":"10.2147\/CMAR.S211363","volume":"11","author":"Z Fan","year":"2019","unstructured":"Fan Z, Fan K, Gong Y, Huang Q, Yang C, Cheng H, et al. The CRP\/albumin ratio predicts survival and monitors chemotherapeutic effectiveness in patients with advanced pancreatic cancer. Cancer Manag Res. 2019;11:8781\u20138.","journal-title":"Cancer Manag Res"},{"key":"10654_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/MPA.0000000000000465","volume":"45","author":"S Mitsunaga","year":"2016","unstructured":"Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Takahashi H, Okuyama H, et al. C-reactive protein level is an indicator of the aggressiveness of advanced pancreatic cancer. Pancreas. 2016;45:110\u20136.","journal-title":"Pancreas"},{"key":"10654_CR25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s13277-010-0044-6","volume":"31","author":"M Haas","year":"2010","unstructured":"Haas M, Laubender RP, Stieber P, Holdenrieder S, Bruns CJ, Wilkowski R, et al. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumour Biol. 2010;31:351\u20137.","journal-title":"Tumour Biol"},{"key":"10654_CR26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317\u201327.","journal-title":"N Engl J Med"},{"key":"10654_CR27","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/bjc.2014.418","volume":"111","author":"T Golan","year":"2014","unstructured":"Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer. 2014;111:1132\u20138.","journal-title":"Br J Cancer"},{"key":"10654_CR28","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1001\/jama.2018.6228","volume":"319","author":"C Hu","year":"2018","unstructured":"Hu C, Hart SN, Polley EC, Gnanaolivu R, Shimelis H, Lee KY, et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA. 2018;319:2401\u20139.","journal-title":"JAMA"},{"key":"10654_CR29","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41591-020-1063-5","volume":"26","author":"Y Nakamura","year":"2020","unstructured":"Nakamura Y, Taniguchi H, Ikeda M, Bando H, Kato K, Morizane C, et al. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med. 2020;26:1859\u201364.","journal-title":"Nat Med"},{"key":"10654_CR30","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.3390\/ijms23031205","volume":"23","author":"A Kasuga","year":"2022","unstructured":"Kasuga A, Okamoto T, Udagawa S, Mori C, Mie T, Furukawa T, et al. Molecular features and clinical management of hereditary pancreatic cancer syndromes and familial pancreatic cancer. Int J Mol Sci. 2022;23:1205.","journal-title":"Int J Mol Sci"},{"key":"10654_CR31","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/cam4.4512","volume":"11","author":"S Tezuka","year":"2022","unstructured":"Tezuka S, Ueno M, Oishi R, Nagashima S, Sano Y, Kawano K, et al. Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI\/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer: a real-world analysis. Cancer Med. 2022;11:1088\u201398.","journal-title":"Cancer Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-10654-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-023-10654-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-10654-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T18:02:48Z","timestamp":1677002568000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-023-10654-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,21]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["10654"],"URL":"https:\/\/doi.org\/10.1186\/s12885-023-10654-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2222318\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,21]]},"assertion":[{"value":"31 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Each patient provided written informed consent for the FOLFOX treatment. This study was conducted in accordance with the Declaration of Helsinki, Ethical Guidance for Studies in Life Science and Medical Science in Humans (by the Ministry of Education, Culture, Sports, Science and Technology, Japan, and the Ministry of Health, Labour and Welfare, Japan). Informed consent was waived due to the retrospective nature of the study, and the study design was approved by the Institutional Review Board of Kanagawa Cancer Center. The study participants were given the choice to opt out of having any information published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"177"}}